Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

NCT07371910 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
HRD-Positive/HER2-Negative Advanced Breast Cancer

Interventions

DRUG: Chemotherapy/ADC Regimen
DRUG: Fluorizoparib
DRUG: Apatinib
DRUG: Physician's Choice Chemotherapy/ADC Regimen

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University